KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Research & Development (2018 - 2026)

Moderna (MRNA) has disclosed Research & Development for 9 consecutive years, with $649.0 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development fell 24.18% year-over-year to $649.0 million; the TTM value through Mar 2026 reached $2.9 billion, down 32.54%, while the annual FY2025 figure was $3.1 billion, 31.06% down from the prior year.
  • Research & Development hit $649.0 million in Q1 2026 for Moderna, down from $775.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.4 billion in Q4 2023 and bottomed at $554.0 million in Q1 2022.
  • Average Research & Development over 5 years is $968.5 million, with a median of $1.1 billion recorded in 2024.
  • Year-over-year, Research & Development skyrocketed 104.15% in 2023 and then crashed 42.67% in 2025.
  • Moderna's Research & Development stood at $1.2 billion in 2022, then increased by 16.1% to $1.4 billion in 2023, then fell by 20.2% to $1.1 billion in 2024, then tumbled by 30.93% to $775.0 million in 2025, then fell by 16.26% to $649.0 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $649.0 million, $775.0 million, and $801.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.